Daily Stock List
Duma Energy Corp. (DUMA)
Alternative Energy, FeedBlitz, MissionIR, SeriousTraders, and Tiny Gems reported earlier on Duma Energy Corp. (DUMA), and we are highlighting the Company today as "One to Watch" here at the QualityStocks Daily Newsletter.
Headquartered in Houston, Texas, Duma Energy Corp. engages in the acquisition, exploration, development, and production of oil and natural gas properties in the continental U.S - on and offshore. Additionally, the Company has a significant interest (39 percent) in a 5.3 million-acre concession in the Republic of Namibia in southern Africa. Duma Energy plans to continue increasing their domestic revenues and cash flow to fuel their aggressive growth through acquisition and participation in high impact international projects.
The Company is actively producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana. They earlier projected domestic production to exceed 1,000 barrels of oil equivalent per day (boepd) by the end of 2012. The Company projects 2,500 (boepd) by the end of 2013. Their primary goals for fiscal year 2013 and beyond are achieving positive cash flow and attaining positive earnings.
Duma successfully drilled their first exploration well in Trinity Bay, Texas. It proves up a large 3D seismic fault block potentially containing more than 5 million barrels of oil. In addition, their plan is to conduct more studies of the Owambo Basin concession in Namibia. The basin appears to have all of the key ingredients for becoming a major oil province. This includes good reservoir and source rocks that extend into southern Angola.
In early December 2012, Duma Energy announced that they received (from Hydrocarb Energy Corp.) additional results from a recent field outcrop study on their concession in northern Namibia. Final lab analyses have indicated significant reservoir porosity and the presence of degraded crude oil.
In-house resource estimates at the structural Oponono Prospect range from 235 million (P90) up to a potential 1.1 billion (P10) barrels of oil. The estimation of P50 resources at Oponono Prospect are 650 million barrels of oil. Additional prospects have undergone identification including reefs and a number of structural traps.
Q1 2013 operational highlights for the Company include positive Cash Flow from Operations of $1.17 million; this was almost double the previous quarter of ($0.63 million). Revenue for the quarter was $2.03 Million. This represents a small increase from the previous quarter ($1.88 million). Total Assets increased to $27.7 million from the previous quarter ($25.8 million).
We're tracking Duma Energy Corp. (DUMA) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.
Duma Energy Corp. (DUMA), closed Thursday's trading session at $2.25, up 2.27%, on 2,545 volume with 5 trades. The average volume for the last 60 days is 5,144 and the stock's 52-week low/high is $1.10/$4.00.
Liberator, Inc. (LUVU)
FeedBlitz reported recently on Liberator, Inc. (LUVU), Penny Dreamers, Buzz Stocks, SimplyBestPennyStocks, Top Best Pennystocks, Stock Roach, StockHideout, InvestorSoup, Penny Stocks Finder, Stock Preacher, Beacon Equity Research, The Stock Psycho did earlier, and we highlight the Company as "One to Watch" here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Liberator, Inc. is a vertically integrated public company capitalizing on the emerging sexual wellness revolution via the global marketing of the Liberator® line of products. Liberator Bedroom Adventure Gear® empowers exploration, fantasy and the communication of desire, for persons of all shapes, sizes and abilities. Products include Liberator shapes and positioning systems, pleasure objects and sensual accessories. Founded in 2002, Liberator has their headquarters in Atlanta, Georgia.
The Company's expansive 140,000 square-foot headquarters consists of offices and production facilities, as well as a distribution center with 15 tractor-trailer docks. The Liberator offices are home to their in-house design, advertising, sales and customer service facilities—all centralized. Liberator employs a multinational staff of more than 120 employees. Liberator's products sell directly to consumers and through hundreds of domestic resellers, on-line affiliates and six international licensees.
Liberator Bedroom Adventure Gear is a love-style brand; it is the kind of luxury found when sexual health and wellness meets ingenious design. Liberator has been at the forefront of bringing love-style furniture into the mainstream lifestyle. Liberator gear fuses visionary and modern designs with the highest quality materials. The Company's products employ angles, elevations, curves, textures, environments and motion to help people, including those with back injuries and other medical conditions, find comfortable ways to connect.
In 2012, Liberator announced the release of TENGA Co., Ltd. created male pleasure items that feature legendary artist and activist Keith Haring's iconic designs. Liberator is the exclusive U.S. distributor for Japan-based TENGA. The Company began a national rollout of the Keith Haring themed line, including sample distribution in popular venues in New York City such as Times Square. TENGA items are well known for their innovative art-centric designs.
Today, Liberator announced the signing of a new three-year, $17 million exclusive marketing and distribution agreement with TENGA. OneUp Innovations, Inc., the operating company of Liberator, has been the exclusive U.S. distributor for Tokyo-based TENGA since 2010. With this new agreement, OneUp Innovations has agreed to purchase JPY 1.25 billion of TENGA products for sale and distribution in the U.S. over the next three years. This represents approximately $17 million in wholesale sales revenue for Liberator - at current exchange rates and at current selling prices.
We're tracking Liberator, Inc. (LUVU) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.
Liberator, Inc. (LUVU), closed Thursday's trading session at $0.081, down 10.00%, on 67,930 volume with 18 trades. The average volume for the last 60 days is 30,062 and the stock's 52-week low/high is $0.022/$0.49.
Primco Management, Inc. (PMCM)
Today we are reporting on Primco Management, Inc. (PMCM), here at the QualityStocks Daily Newsletter.
Primco Management, Inc., a real estate management holding company, offers real estate management services. The Company is a development stage enterprise. Their intention is to provide real estate management services to a range of properties. In addition, the Company's intention is to offer consulting services. Primco Management's shares trade on the OTC Bulletin Board. Founded in 2010, the Company has their corporate headquarters in Mississauga, Ontario.
Primco Management is focusing on providing their real estate management services to properties such as class A office space, industrial, manufacturing, and warehousing facilities, and data centers and retail outlets for real estate users. The Company is additionally focusing on offering their consulting services, consisting of site selection, feasibility studies, exit strategies, market forecasts, strategic planning, as well as research services. However, Primco Management has neither engaged in any material operations nor generated any significant revenues as of their most recent Quarterly Report – October 31, 2012.
For the nine months ended September 30, 2012, Primco Management had revenues of $2,600. The Company had accounting expenses of $5,900, bank service charges of $40, consulting expenses of $14,200, and research and development expenses of $110,000. This resulted in total operating expenses of $130,140 for the period. They had a net loss of $127,540 for the nine months ended September 30, 2012.
For the period from Inception (October 14, 2010) through September 30, 2012, Primco generated revenues of $6,185. The Company had accounting expenses of $23,556, bank service charges of $214, consulting expenses of $40,200, legal and professional expenses of $18,999, research and development costs of $110,000 and state filing fees and permits of $1,500. Therefore, they had total operating expenses of $194,469 for the period. For the period from Inception (October 14, 2010) through September 30, 2012, Primco had a net loss of $188,284.
Today, Primco Management announced that ESMG, Inc. has taken controlling interest in the Company via the acquisition of more than 80 percent of the outstanding shares. ESMG (Eat Sleep Media Group) is a fully integrated entertainment company. ESMG has interests in music, film, television, internet radio and sports.
Primco Management, Inc. (PMCM), closed Thursday's trading session at $0.185, up 23.33%, on 11,568,789 volume with 1,349 trades. The average volume for the last 60 days is 15,212 and the stock's 52-week low/high is $0.0125/$0.425.
biOasis Technologies, Inc. (BTI.V)
Today we are highlighting biOasis Technologies, Inc. (BTI.V), here at the QualityStocks Daily Newsletter.
biOasis Technologies, Inc. is a biopharmaceutical company that lists on the TSX Venture Exchange. The Company, based on Transcend, biOasis proprietary brain delivery platform, is focusing on creating new drugs that can cross the blood-brain barrier (BBB) to address unmet medical needs in the treatment of brain diseases. These diseases include neurodegeneration, metastatic cancer and metabolic diseases. biOasis Technologies has their headquarters in Vancouver, British Columbia.
The Company's business strategy concentrates on out-licensing their technologies to qualified partners. In addition, their strategy emphasizes strategic acquisitions of products and technologies relevant to the diagnosis and management of central nervous system (CNS) diseases and disorders.
biOasis' Commercial Programs include Cognitest™ - a blood test designed to identify patients afflicted with Alzheimer's disease. Another program is Transcend™ - a carrier for delivery of therapeutic agents across the BBB.
Transcend-Herceptin® Conjugate (BT2111) is a conjugate between biOasis' Transcend brain delivery vector and trastuzumab (Herceptin®), a humanized monoclonal antibody used clinically in the treatment of HER2+ breast cancer. It is reported that up to 35 percent of HER2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. biOasis is researching the potential of BT2111 for treatment of HER2+ metastatic breast cancer in the brain, due to its ability to deliver Herceptin®, across the blood-brain barrier.
Today, biOasis Technologies announced that their Transcend-Herceptin® Conjugate (BT2111) product candidate (a proprietary conjugate of Roche's anti-cancer antibody trastuzumab (Herceptin®) and Transcend, biOasis brain delivery vector) reduced the number of metastatic human HER2+ breast cancer tumors in the brains of test animals by 68 percent when compared to untreated control animals.
The tumors that remained after treatment were 57 percent smaller than those in the untreated control animals. In contrast, Herceptin alone had no effect on reducing the number of tumors. It was associated with only a slight (15 percent) reduction in tumor size when compared to untreated control animals. The Company believes that these results provide clear evidence of the potential of the biOasis Transcend-Herceptin® Conjugate (BT2111) for treating brain metastasis.
biOasis Technologies, Inc. (BTI.V), closed Thursday's session at $1.68, up 15.86%, on 347,195 volume. The stock's 52-week low/high is $1.09/$2.13.
Gilla, Inc. (GLLA)
We are reporting on Gilla, Inc. (GLLA), here at the QualityStocks Daily Newsletter.
Gilla, Inc. is a mineral-property development company specializing in acquiring and consolidating mineral properties with production potential, and future growth through exploration discoveries. On June 25, 2012, the Company entered into a Letter of Intent (LOI) to acquire all of the outstanding common shares of Snoke Distribution Canada Ltd. Snoke Distribution is the holder of a distribution agreement with German manufacturer Ecoreal GmbH & Co. KG for the exclusive rights to distribute all Snoke electronic cigarette (e-cigarette) products in North America, the UK, Mexico and the Caribbean. Gilla lists on the OTCQB; the Company is based in Carson City, Nevada.
The Company's acquisition and development emphasis focuses on properties containing precious metals and/or other strategic minerals that are located in Canada.
Moreover, concerning e-cigarettes, the Snoke Rights have a five-year term. They automatically renew in perpetuity unless there is a breach of the distribution agreement or Snoke Distribution becomes insolvent.
The Snoke e-cigarette was invented by leading German Oncologist Dr. Jürgen Ruhlmann. It is the only e-cigarette manufactured in Germany and is done so to the GMP2000 pharmaceutical standard. The Snoke comes in a premium version, which is rechargeable, and a disposable version that is the equivalent of 1.5-2 packages of regular cigarettes.
SNO-Caps are the inhaled flavor packages inside the tip. These are available in nicotine and non-nicotine. They come in a range of flavors: tobacco, tobacco mild, mint, menthol, coffee, espresso, chocolate, vanilla, apple, cherry, green tea, and energy.
Gilla announced in mid-November 2012, that further to the LOI signed on June 25, 2012 and in accordance with the terms of the LOI, Gilla announced that they completed the acquisition of all of the outstanding common shares of Snoke Distribution Canada. This was via the issuance of 29.4 million common shares (inclusive of a Private Placement) of Gilla to the shareholders of Snoke Distribution.
Gilla, Inc. (GLLA), closed Thursday's trading at $0.041, even for the day, on 10,000 volume with 1 trade. The average volume for the last 60 days is 17,144 and the stock's 52-week low/high is $0.005/$0.12.
Microelectronics Technology Co. (MELY)
Pennystocknet reported recently on Microelectronics Technology Co. (MELY), Fast Moving Stocks, Stocktwiter, HotStockProfits, Actual Gains, PennyStockRumors.net did earlier, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Microelectronics Technology Co. is a cloud computing internet technology incubator. Listed on the OTC Markets' OTCQB, the Company provides cloud technology and services targeting small business. Incorporated in the State of Nevada on May 18, 2005, Microelectronics Technology has four mineral claims located near Wawa in northern Ontario, that they one day plan to explore for precious metals. However, the Company has put their plans to explore these claims on hold because of their acquisition of Cloud Data on August 26, 2011. Microelectronics Technology has their corporate headquarters in Monarch Bay, California.
Through the acquisition of Cloud Data, Microelectronics Technology is moving into the Internet incubator arena. This is to benefit from the technology opportunities available today and in the immediate future within the cloud-computing marketplace. In September 2012, Cloud Data signed WeatherCity Services as a new Server Client. WeatherCity provides weather forecasts to more than 62,000 cities in more than 121 countries using their innovative computer forecasting system. Weather City is forecasting expansion in 2013 to 2 million cities with over 30 million page views per month.
Last month, Cloud Data Corp., the wholly owned subsidiary of Microelectronics Technology announced the launch of their new Dedicated Server Hosting Platform. The Platform was created from the ground-up to accommodate the needs of modern dedicated server customers, with features that are unique to the market. The Dynamo Servers Platform will enable customers to build private clouds and custom Platform as a Service (PaaS) solutions easily. Cloud Data is using the platform to build their upcoming Sproq.com Platform as a Service offering.
At the end of January 2013, Microelectronics Technology announced that Cloud Data's new business center the Dynamo Server Division, is ahead of internal projected revenues. The Dynamo server division is now offering valued priced dedicated server rentals to third party customers. The servers are located within Canada in their Point of Presence (POP) in Vancouver, British Columbia, with expansion plans for the next quarter to include Chicago, Illinois and Dallas, Texas. In addition to the Dynamo dedicated server offering, the Vancouver co-location will also house Cloud Data's Sproq.com servers. Dynamo servers provide powerful cloud servers to clients and are the basis for the hardware architecture that Sproq.com is built on.
Microelectronics Technology Co. (MELY), closed Thursday's trading session at $0.025, down 1.57%, on 295,300 volume with 10 trades. The average volume for the last 60 days is 194,116 and the stock's 52-week low/high is $0.0075/$0.45.
Serengeti Resources, Inc. (SIR.V)
Stockhouse and Greenbackers reported previously on Serengeti Resources, Inc. (SIR.V), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Serengeti Resources, Inc. is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company is presently moving forward their Kwanika copper-gold project and exploring their broad portfolio of properties in the highly prospective Quesnel Trough of British Columbia (B.C.). Serengeti Resources has their headquarters in Vancouver, B.C.
Their property portfolio in B.C. consists of 11 properties, 100 percent Company owned, totalling 72,000 hectares, and 12 properties Quest (64 percent JV) totalling 41,000 hectares; Fjordland Exploration, Inc. (36 percent). Concerning Mines & Major Projects, Serengeti properties include Kwanika, Croy-Bloom/Davie Ck., Germansen, Choo, Tchentlo, Valleau, Osilinka, and Fleet.
The Company is also focusing on exploring for gold and silver (Ag) in the Altiplano region of Northern Mexico. Serengeti believes that the Mexico silver-gold properties offer good upside potential in an emerging trend. They have a large land position in North-Central Mexico's premier silver-gold district. There is an emerging major Ag-Au-Zn-Pb mineralized trend in the region.
Serengeti has the 30,048-hectare Cristobal claim next to the plus 300 million oz Ag Cordero-Sanson deposit. Nearby claims cover multiple targets including an identified Au-Zn system at Victoria. A prospective property portfolio is available for sale or joint venture
In November 2012, Serengeti Resources reported the results of a prospecting and surface rock sampling program conducted in September 2012 on the Croy Bloom property. This property is 85 kilometers South of AuRico Gold's Kemess Mine in the Quesnel Trough of north-central B.C.
The objectives of the 2012 exploration program were to evaluate an area known as the Karen Cirque and Saddle Gulley Zone, follow-up on a gold-copper-bearing stratiform magnetite unit; and further investigate gold and copper vein, stockwork and porphyry style mineralization historically described to occur in this area of the property. Several rock grab samples returned high-grade gold and copper values in an area of the property considered to be highly prospective.
Yesterday, Serengeti Resources announced the completion of an independent NI 43-101 compliant Preliminary Economic Assessment (PEA) for their 100 percent owned Kwanika copper-gold porphyry project located in the Quesnel Trough of North-Central B.C. The results of the PEA demonstrate the potential technical and economic viability of establishing a new copper-gold mine and mill complex on the property.
PEA highlights include a pre-tax NPV 5 percent of CDN $263 million, a 13.4 percent IRR, and a 13.5 year mine life. Highlights also include a Life of Mine (LOM) payable production of 545 million pounds copper, 489,000 ounces gold, 2.45 million ounces silver and 5.25 million pounds molybdenum. Additionally, highlights include an initial capital cost of CDN $364 million plus LOM sustaining capital of $144 million for a 15,000 tpd (5.5 million tpa) mill and combined open pit, underground mining operation.
Serengeti Resources, Inc. (SIR.V), closed Thursday's session at $0.08, down 11.11%, on 17,600 volume. The stock's 52-week low/high is $0.06/$0.25.
Strata Oil & Gas, Inc. (SOIGF)
AllPennyStocks reported previously on Strata Oil & Gas, Inc. (SOIGF), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCBB, Strata Oil & Gas, Inc. engages in the exploration and development of bitumen from carbonates in Alberta. The Company is focusing on high-value carbonate-hosted bitumen deposits in North America. Their emphasis is on full-cycle exploration. Strata Oil & Gas believes that they can have a greater impact by developing their own exploration projects rather than acquiring advanced projects from others. Founded in 1998, Strata Oil & Gas is based in Calgary, Alberta.
Currently, Strata Oil & Gas holds a 100 percent interest in 52,480 acres (approximately 82 sections) of oil sands leases in the Peace River region of Alberta's Carbonate Triangle. The Company's Cadotte project has undergone independent evaluation, with a contingent resource of 517 million recoverable barrels and a Net Present Value (NPV) of $1.3 billion (28 percent IRR). There exists 1.99 Billion bbls in place.
Pertaining to their development & production plan, Strata is going ahead with a $250 million five-phase capital plan to produce 56,000 bbls per day over 20 years. Phase 1 is underway with engineering, exploration and pre-production development of the Cadotte holdings.
In addition, the Company has an additional 1,280 acres (2 sections) in the Wabasca region. The estimation is that this region contains greater than 94 billion barrels of oil (Alberta Department of Energy, Cold Heavy Oil Production With Sand In The Canadian Heavy Oil Industry, Dr. Maurice Dusseault, March 2002).
In August 2012, Strata Oil & Gas announced the appointment of Dr. Michael J. Ranger to the Company's Board of Directors. Dr. Ranger is a well-respected expert in the petroleum industry with a prolific career providing services to an array of the world's largest oil companies.
At present, he is an independent petroleum consultant and is a Director of Canadex Resources Ltd. Before this, he served on the Scientific Advisory Board of Gushor, Inc. from 2007 to 2009, and as a senior geologist at Gulf Canada Resources between 1977 and 1985.
Concerning resources, Mr. Ron Daems, President of Strata Oil & Gas, stated, "The carbonate-hosted bitumen resources of Alberta are the next frontier in the North American oil industry. Like oil sands two decades ago, carbonates represent an enormous and relatively untapped petroleum resource."
Strata Oil & Gas, Inc. (SOIGF), closed Thursday at $0.15, up 15.38%, on 35,200 volume with 9 trades. The average volume for the last 60 days is 37,943 and the stock's 52-week low/high is $0.035/$0.20.
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.139, up 27.52%, on 11,376,861 volume with 727 trades. The stock’s average daily volume over the past 60 days is 3,718,549, and its 52-week low/high is $0.0275/$0.1549.
Advaxis, Inc., the clinical-stage biotech firm which is at the forefront of developing next-gen immunotherapies for cancer and infectious disease, reported today that the company will be offering a comprehensive look at their advanced pipeline this February 11, during the 15th Annual BIO CEO & Investor Conference in NYC at the Waldorf Astoria, 9:30AM, in the Basildon room. Chairman and CEO of ADXS, Thomas Moore, will be on-hand to provide additional data and directly field questions on the company's 110-patient Phase II study of ADXS-HPV in recurrent/refractory cervical cancer being done in India.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Present at the 15th Annual BIO CEO & Investor Conference
Advaxis to Present at the 6th Annual OneMedForum
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.79, off by 1.25%, on 2,200 volume with 3 trades. The stock’s average daily volume over the past 60 days is 1,876, and its 52-week low/high is $0.06/$3.10.
VistaGen Therapeutics, Inc. reported a significant advancement today in their University Health Network-licensed stem cell technology which applies to both induced pluripotent stem cells and embryonic stem cells, enabling extremely efficient production of the valuable mature hematopoietic (blood) precursor cells which become the majority of all blood cells in the body. This advancement supercharges the company's capacity to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders, something covered in the December 2012 edition of the open-access journal Cell Reports.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Bergamo Acquisition Corp. (BGMO)
The QualityStocks Daily Newsletter would like to spotlight Bergamo Acquisition Corp. (BGMO). Today, Bergamo Acquisition Corp. closed trading at $0.04, on 1,025,662 volume (5x the 30-day average) with 8 trades. The stock’s average daily volume over the past 60 days is 177,529, and its 52-week low/high is $0.01/$0.07.
Bergamo Acquisition Corp. (BGMO) is a global investor targeting a diversified portfolio of large corporate and middle-market companies for sole acquisition and co-investment alongside other sophisticated investors such as private equity funds, hedge funds, investment banks, and other institutions. The company has engaged investments in financial instruments and companies worldwide.
Alternative energy is a key focus of the company. Bergamo Acquisition has developed solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems to meet the vast needs of emerging markets. The company’s turnkey solutions help developers, utilities, water districts, power plant owners, and industrial customers diversify their existing generation portfolio.
Bergamo Acquisition executes energy projects from concept through completion, offering design, construction management, and facility maintenance services. Together with pre-designed and packaged Balance of Plant and standardized Power Plant Control Modules, the company enables rapid project commissioning and provides an optimum balance between capital cost, plant performance, and operational and maintenance expenses.
The company’s technical team has been working with government officials, manufactures, and importers in Asia, Africa, and the Middle East to introduce its state-of-the-art technology. Investable funds are already in place to pursue investment opportunities in these and other countries. Bergamo Acquisition relies on its extensive network within the global institutional investment and banking industries to source the best opportunities. Disclaimer
Bergamo Acquisition Corp. Company Blog
Bergamo Acquisition Corp. News:
Bergamo Acquisition Corp. Provides Authenticated Documentation to Confirm Bank Deposits
L.L. Bradford Letter Confirms Funding Reported by Bergamo Acquisition Corp.
Bergamo Acquisition Corp. Signs Investment Agreement
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.3, up 3.45%, on 27,837 volume with 5 trades. The stock’s average daily volume over the past 60 days is 11,217, and its 52-week low/high is $0.18/$1.87.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Comments on Recent Balance Sheet Improvements, Channel Partners and Market Opportunities
GlobalWise CEO to Speak at Technology United Executive Conference
GlobalWise Launching Sales Campaign With Public Safety Market Leader Tiburon
Advaxis, a biotech developing the next-generation of immunotherapies for cancer and infectious diseases, announced it will present at the 15th Annual BIO CEO & Investor Conference on February 11th at 9:30am EST in the Basildon room at the Waldorf-Astoria in New York City.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Thomas Moore, Chairman and CEO of Advaxis, will provide additional information on its Phase 2 study of ADXS-HPV in recurrent/refractory cervical cancer in 110 patients in India. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
In addition to providing ongoing social media coverage of the conference, MissionIR will issue a special broadcast to subscribers profiling companies scheduled to deliver a presentation. To sign up for The Mission Report, visit www.MissionIR.com.
VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, earlier today announced significant advancements in its stem cell technology licensed from the University Health Network (UHN) in Toronto, Canada. The advancements improve the company’s ability to develop new stem cell-based bioassay systems and potentially improved cell therapies for human blood system disorders.
“In collaboration with our long-term strategic partners at UHN, we continue to pioneer stem cell technology that promises to change the way we develop medicine and apply treatment,” stated Shawn K. Singh, CEO of VistaGen. “In addition to creating new capabilities and in vitro assays for drug rescue and predictive toxicology, these advancements open the door to development of new treatments for bone marrow failure, anemia, viral diseases and other conditions that compromise the immune system.”
“Due to only partial understanding of the timing and control of the development of definitive hematopoiesis in humans, scientists were previously limited in their ability to identify and produce, from human pluripotent stem cells, the important precursor for mature red and white cells of the blood,” commented H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer. “The identification and characterization of this important precursor provides a readily accessible pluripotent stem cell-derived target cell population that can be expanded and matured into the types of cells needed for novel in vitro assays and our drug rescue efforts, and enables improved technologies and approaches for future cell therapy collaborations.”
Dr. Gordon Keller, Chairman of UHN’s McEwen Centre for Regenerative Medicine in Toronto and co-founder of VistaGen, added, “We’ve been working for many years studying in vitro differentiation of pluripotent stem cells trying to identify, and then expand, the first human cell capable of producing the adult blood and immune system. I believe that we now have a better understanding of this important transition from embryonic to adult hematopoiesis, and have the tools to develop improved methods to expand this cell in large numbers for both drug development and cell therapy applications.”
For more information, visit www.VistaGen.com
Enterprise Content Management (ECM), defined loosely as the procedures and technologies companies must increasingly use to manage the growing number of documents critical to enterprise operations, is finding its way into virtually every industry. GlobalWise Investments, through its Intellinetics subsidiary, empowers organizations to dig their way out of information overload so they can operate faster, leaner, and smarter. Their content management software, deployed via the cloud or premise, delivers real economic and operational value by enabling documents and records to flow freely when and where they need to. In particular, their cloud based option makes it possible to access needed information 24/7 from anywhere in the world.
The GlobalWise/Intellinetics ECM solutions continue to expand into new areas of application. Below is a general breakdown of the company’s reach:
• Human Resources
• Public Records Requests
• Patient Records
• Public Sector – Developmental Disabilities, Metro Housing Authority
• Education – K-12, Higher Education, Special Education
• Law Enforcement / Corrections
• Manufacturing & Distribution
• Financial Services
The company’s Intellivue Document Management Platform is an intelligent technology platform, designed for easy integration into existing host business applications. The system provides standardized business processes to organize a client’s paper or unstructured electronic files into process ready information. Through partnerships with industry leaders, such as Samsung, Lexmark, and Dell, document capturing is made an easy part of the normal business flow, with fixed cost models that appeal to a wide customer base. Growing demand, together with the company’s expanding channel sales building efforts, have led to expected revenue growth in the 50% range.
TransAct Energy, the San Antonio-headquartered sustainable energy developer with its hands in many different aspects of the space from waste/energy conversion to wind, solar, and even geothermal, took some time out today to update markets on the previously announced (July 18, 2012) joint development agreement (JDA) with Mr. Bruce Hutchon, Utopial Limited, and Halfuel Limited.
The JDA-formed joint entity has Hutchon transferring his proprietary, emissions-free, and exceptionally clean waste-to-energy technology, as well as the operating 20 tonne pilot plant and all the associated research done thus far, over to the new joint corporation structure. TransAct will kick in some $100M for a new plant that is slated to be built in Scotland and will execute a comprehensive five-year business plan designed to take the new entity into fruition.
This plan is already complete and the initial plant design looks like it will be a 500 tonne/day refuse-derived fuel operation capable of generating an estimated $160M annually (EBITDA). The location is ideal and the target feedstock for the facility is already identified as well. With the necessary supplier proceedings already begun, TEGY shareholders have been put in the pole position to profit off of this considerable logistical growth.
Similarly, consumers for the end products, which range from electricity and fuels like liquid petroleum gas, to carbon black, have been engaged with the market price for such commodities established as a benchmark during deliberations. This deal brings the technical might of the esteemed Hutchon and his group of private UK-based chemical tech companies to the table and the JDA will benefit heartily from this vast sum of experience in developing cutting-edge chemical/process solutions. A vast sum of experience which grew out of a long, successful track-record in the plastics industry where a deep, intimate understanding of commercial organic chemistry helped establish Hutchon’s powerbase (Insitefuel Limited, Polyformers Limited, and Utopial Limited).
CEO of TEGY, Rod Bartlett, praised the efforts made thus far, noting that work completed during the initial phases of the JDA by both sides has yielded seriously advantageous insights that will translate directly into bottom-line efficiency metrics as the full-scale plant comes to life. Just getting everyone at the same table has helped move the ball down the field in exciting ways conceptually and everyone at TEGY is “extremely optimistic” about huge forward momentum for the company’s waste-to-energy segment, according to Bartlett.
Bartlett expressed a kind of sage confidence in the potential of this operation and projected major benefits as a result, not just to the clean energy sector as a whole, but specifically to TEGY shareholders, who stand poised to reap the rich rewards of being at the tip of the spear in the fight to create a sustainable energy future. Emissions-free energy and end products like carbon black from carbonaceous waste, enabled by innovative process technology like that developed by Hutchon, promises to transform the face of the planet’s waste cycle and this 500 tonne plant will be a big step forward in the right direction.
For more information on TransAct Energy Corp. check out their newly redesigned Web site at www.TransactEnergyCorp.com
Today's Top 3
Investor News Source
Wall Street Resources
The QualityStocks Public Company Sponsor News